The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pharmacologic and pharmacometric studies of factors affecting the pharmacokinetics and pharmacodynamics of antibody drug conjugate anetumab ravtansine in patients with solid tumors.
 
Li Chen
Employment - Allucent
 
Andrew Lucas
Employment - PumasAI
 
Julie Dumond
No Relationships to Disclose
 
Aaron Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genzyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Johnson & Johnson Global Services (Inst); Takeda (Inst)
Speakers' Bureau - Chugai/Roche (Inst)
Research Funding - Bristol Myers Squibb (Inst); Novartis (Inst); Verily (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
Other Relationship - Mesothelioma Applied Research Foundation
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Repare Therapeutics; Roche/Genentech; Seagen; Zai Lab
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Schrodinger (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline (Inst)
 
Anna Spreafico
Consulting or Advisory Role - Alentis Therapeutics; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Nubiyota (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)
 
Claire O’Connor
No Relationships to Disclose
 
Beth Zamboni
No Relationships to Disclose
 
Kashish Patel
No Relationships to Disclose
 
Jeffery Moscow
No Relationships to Disclose
 
William Zamboni
Employment - ChemoGLO (I); Glolytics (I); MediGLO (I); MediGLO (I)
Leadership - ChemoGLO; ChemoGLO (I); Glolytics; Glolytics (I); MediGLO
Stock and Other Ownership Interests - ChemoGLO; ChemoGLO (I); Glolytics; Glolytics (I); MediGLO
Consulting or Advisory Role - Adaptimmune; Akagera; ChemoGLO; Eagle Pharma; GlaxoSmithKline; Glolytics; Inimmune; NuVeta Radiotherapy; OBI Pharma; Xcovery
Research Funding - CBT Pharmaceuticals; ChemoGLO; Genentech; Glolytics; Inimmune (Inst); MabVax; Merrimack; Meryx Pharmaceuticals; OBI Pharma; SciTech (Inst); Xcovery (Inst)
Patents, Royalties, Other Intellectual Property - Biomarkers of MPS Function (controlled by Glolytics) and MPS FcRs (controlled by UNC); ChemoGLO Wipe Kits and HDClean cleaning products
Travel, Accommodations, Expenses - ChemoGLO; Glolytics; Syros Pharmaceuticals